PLX647 is a highly selective, orally active dual inhibitor of FMS and KIT kinases, with potential therapeutic applications in diseases driven by these kinases, such as certain leukemias and inflammatory disorders. It potently inhibits the proliferation of BCR-FMS- and BCR-KIT-expressing cells, as well as FLT3–ITD-expressing MV4-11 cells. PLX647 also suppresses osteoclast differentiation and bone osteolysis, and demonstrates efficacy in reducing macrophage accumulation, systemic inflammation (e.g., LPS-induced TNF-α and IL-6 release), and disease progression in a collagen-induced arthritis mouse model. Additionally, it prevents tumor-induced bone damage in vivo.